Pharmaceuticals
The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Feb. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-02-23 09:22
5354
Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A
LACHEN, Switzerland, Feb. 23, 2021 /PRNewswire/ -- Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journalThrombosis and Haemosta...
2021-02-23 00:51
2661
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41
SHANGHAI, Feb. 21, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of nonalcoholic steatohepatitis (NASH), announces the positive clinical results in overweight and obese subjects...
2021-02-21 19:30
3481
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines
2021-02-18 12:26
6038
Luye Pharma and Towa Pharmaceutical Enter Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan
BASEL, Switzerland, Feb. 18, 2021 /PRNewswire/ -- Luye Pharma Group announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Towa Pharmaceutical Co., Ltd. (Towa), the terms of which grant Towa exclusive rights to the development and commercialization of Rivastig...
2021-02-18 11:24
3048
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
- The U.S. Phase 2/3 study with once-daily, orally-administered RHB-107 (upamostat) evaluates treatment of patients with symptomatic COVID-19 who do not require hospitalization - the vast majority of patients - RHB-107 is a novel serine protease inhibitor targeting human cell factors involved in...
2021-02-17 20:00
3418
Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
Onward Also Makes an Equity Investment in Biomunex LAUSANNE, Switzerland, Feb. 16, 2021 /PRNewswire/ -- Onward Therapeutics SA (Onward) announced today the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS (Biomunex),Paris, France, of a b...
2021-02-16 13:00
1809
Invitation to the presentation of Elekta's third quarter 2020/21
STOCKHOLM, Feb. 15, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the third quarter 2020/21 at10:00 a.m. CET on February 25. The interim report for the third quarter will be published at 7:30 a.m. CET on the same day. The company's development will be...
2021-02-15 20:37
4535
Kungl. Vetenskapsakademien: New knowledge about a cancer pharmaceutical led to the Sjöberg Prize
MALMÖ, Sweden, Feb. 15, 2021 /PRNewswire/ -- Benjamin L. Ebert, USA, receives this year's Sjöberg Prize, worthone million US dollars, for his research into how lenalidomide works as a treatment for blood cancer. His discovery of the mechanism that promotes protein breakdown in cancer cells may be...
2021-02-15 20:35
1715
Ascletis Joins Sagimet's US$80 Million in Crossover Financing with Premium Investors
HANGZHOU, China and SHAOXING, China, Feb. 11, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that Ascletis, through its wholly-owned subsidiary, participates in Sagimet Biosciences Inc.'sUS$80 million in crossover financing, led by an undisclosed public equity healthcare ...
2021-02-11 22:30
10486
'Supercharger' to revive mainstay antibiotic in global fight against antibiotic resistance
MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- SuperTrans Medical (STM), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacteria, has published First-In-Class, successful pre-clinical results and announced plans to begin clinica...
2021-02-11 06:00
2399
Abbott's Fast, Reliable and Convenient COVID-19 Tests Ramp Up Indonesia's Testing Capability
- Southeast Asia's most populous nation1 expands use of fastest available molecular point-of-care technology and an antigen rapid test device that needs just a nasal swab, to detect active coronavirus infections at massive scale - Delivering reliable results in minutes, Abbott's COVID-19 testing ...
2021-02-10 23:14
7855
Elekta's ProKnow to help standardize radiotherapy for veterans
Cloud-based ProKnow will enable peer review across Veterans Affairs network ATLANTA, Feb. 10, 2021 /PRNewswire/ -- Elekta announced today that the United States Department of Veterans Affairs (VA) National Radiation Oncology Program is poised to pair its major radiotherapy quality program with El...
2021-02-10 21:25
6080
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial
BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the successful completion of dosing of the first pati...
2021-02-10 19:51
1880
New 3M™ Polisher™ ST reduces the number of biopharma manufacturing process steps
ST. PAUL, Minn., Feb. 9, 2021 /PRNewswire/ -- 3M Health Care launched 3M™ Polisher™ ST,* an advanced, single-use AEX solution designed to replace reusable AEX polishing column for biologic drug manufacturing. Polisher ST improves the biopharma manufacturing workflow by reducing the number of pro...
2021-02-10 00:07
5727
endpoint Clinical Announces the Appointment of Christine Hurley as its Senior Vice President, Client Services
SAN FRANCISCO, Feb. 9, 2021 /PRNewswire/ -- endpoint Clinical, an industry-leading global interactive response technology (IRT) company, has appointed Christine Hurley as its Senior Vice President, Client Services. Bringing over 20 years of experience in clinical operations and technology, Chri...
2021-02-09 22:00
3279
neoX Biotech closes US$30 million Series A round
BEIJING, Feb. 9, 2021 /PRNewswire/ -- neoX Biotech, a next-generation biotech company specializing in computational design for novel drug research and development, recently announced that it had raisedUS$30 million in Series A funding.The financing was co-led by Sky9 Capital and 5Y Capital (forme...
2021-02-09 21:28
2831
Regent Pacific's Strategic Partner Obtains Clinical Trial Approval for FORTACIN(TM)
HONG KONG, Feb. 9, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce that Wanbang Biopharmaceutical...
2021-02-09 20:35
7852
Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China
TORONTO and SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance Pharma for commercialization in theGreater China region. Nuance is a biopharmaceutical company focused on licensing, developing and com...
2021-02-09 20:00
5177
Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China
SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Yingli Pharma announced today that it reached strategic collaboration with Hengrui Medicine (600276.SH), a partnership which will significantly accelerate the expansion of Yingli Pharma's oncology business inChina, the second largest pharmaceutical market in...
2021-02-09 08:30
1616
Week's Top Stories
Most Reposted
k-ID Closes $45 Million Series A from Andreessen Horowitz and Lightspeed Venture Partners to Set a New Global Benchmark for Age-appropriate Gaming Experiences
[Picked up by 320 media titles]
2024-06-25 21:00
10 Start-ups Awarded in HK Tech 300 Southeast Asia Start-up Competition Fostering Innovation & Entrepreneurship Beyond Boundaries
[Picked up by 318 media titles]
2024-06-27 18:56
Labuan IBFC Inc. and STEP Malaysia jointly host wealth management and estate planning event
[Picked up by 317 media titles]
2024-06-28 12:45
SCO strengthening youth development for better future
[Picked up by 297 media titles]
2024-06-24 10:52
Fibocom Drives the Rapid Growth in the Economics of IoT Scale with Ultra-compact size Cat 1 bis Module MC610-GL at MWC Shanghai 2024
[Picked up by 286 media titles]
2024-06-26 10:00
Most Read
k-ID Closes $45 Million Series A from Andreessen Horowitz and Lightspeed Venture Partners to Set a New Global Benchmark for Age-appropriate Gaming Experiences
2024-06-25 21:00
13261
Lilyannie Christie Linus Crowned Miss Grand Malaysia Sabah 2024
2024-06-25 13:38
12438
SCO strengthening youth development for better future
2024-06-24 10:52
7198